Proactive Investors - Run By Investors For Investors

Neurotrope welcomes industry veteran to board

Neurotrope, which is developing a disruptive therapy for the treatment of severe Alzheimer’s disease, has appointed an industry veteran to the board.
Neurotrope welcomes industry veteran to board
Dr Susanne Wilke will replace Larry Alstiel, who resigned to pursue a new, full-time professional opportunity...

Neurotrope (OTCMKTS: NTRP), which is developing a disruptive therapy for the treatment of severe Alzheimer’s disease, has appointed an industry veteran to the board.

Dr Susanne Wilke will replace Larry Alstiel, who resigned to pursue a new, full-time professional opportunity.  

"We are very pleased to welcome Susanne to our board," said Charles S. Ramat, President and CEO of Neurotrope.

"She is an industry veteran with a tremendous scientific background including a dual Ph.D. in Chemistry and Biochemistry and extensive understanding of various therapeutic areas.

"Susanne’s proven experience in scientific operations, strategic planning and managing the growth of emerging companies will prove invaluable as we advance Bryostatin-1 through our Phase 2b proof-of-concept trial in moderately-severe to severe Alzheimer’s disease.”

Wilke is the Co-founder and CEO of CrossBridge International, an advisory specializing in integrating proprietary scientific developments with sophisticated marketing and financing plans for biotech companies.

Dr. Wilke also served as Director of the Life Sciences group at Wombat Capital Markets SAS, a financial advisory firm specializing in cross-border transactions between the U.S. and Europe.

Neurotrope has successfully completed a Phase 2a trial, in which all primary endpoints were met, and is currently dosing patients in a Phase 2b proof-of-concept trial.

View full NTRP profile View Profile

Neurotrope Timeline

Related Articles

cancer
February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
cannabis
February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use